BCAX
Bicara Therapeutics Inc. Common StockBCAX
BCAX
About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
229% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 7
75% more funds holding in top 10
Funds holding in top 10: 4 [Q3] → 7 (+3) [Q4]
63% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 24
22% more funds holding
Funds holding: 68 [Q3] → 83 (+15) [Q4]
19.0% more ownership
Funds ownership: 66.83% [Q3] → 85.82% (+19.0%) [Q4]
12% less capital invested
Capital invested by funds: $926M [Q3] → $814M (-$112M) [Q4]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
46%
downside
Avg. target
$24
62%
upside
High target
$44
197%
upside
4 analyst ratings
3 positive
75%
0 neutral
0%
1 negative
25%
Wells Fargo Eva Fortea Verdejo 25% 1-year accuracy 2 / 8 met price target | 46%downside $8 | Underweight Initiated | 17 Apr 2025 |
HC Wainwright & Co. Robert Burns 23% 1-year accuracy 40 / 172 met price target | 197%upside $44 | Buy Maintained | 7 Apr 2025 |
Cantor Fitzgerald Eric Schmidt 23% 1-year accuracy 6 / 26 met price target | 12%downside $13.01 | Overweight Reiterated | 13 Mar 2025 |
Wedbush David Nierengarten 40% 1-year accuracy 46 / 114 met price target | 109%upside $31 | Outperform Reiterated | 12 Feb 2025 |
Financial journalist opinion
Based on 3 articles about BCAX published over the past 30 days
Neutral
GlobeNewsWire
2 hours ago
Bicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025
BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced multiple presentations related to ficerafusp alfa at the American Association for Cancer Research (AACR) Annual Meeting 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.
Neutral
GlobeNewsWire
5 days ago
Bicara Therapeutics to Present Updated Data from Ongoing Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that updated data from the company's ongoing Phase 1/1b clinical trial of ficerafusp alfa in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) will be highlighted in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30-June 3, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.
Positive
Seeking Alpha
1 week ago
Bicara: Innovative Precision Tumor Targeting
Bicara Therapeutics' lead candidate, ficerafusp alfa, targets EGFR and TGF-beta in tumors, showing promise in hard-to-treat cancers like Head and Neck Squamous Cell Carcinoma. Bicara's financial health is robust, with $489.7 million in cash, ensuring operations through mid-2029, bolstered by a successful IPO and Series C funding. Early clinical data for ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC shows significant antitumor activity and manageable safety, supporting its potential market impact.
Neutral
GlobeNewsWire
1 month ago
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting Strong financial position with approximately $490 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. “2024 was a remarkable year for Bicara, marked by our successful transition to a public company, the advancement of our lead asset, ficerafusp alfa, and the addition of key leaders to our executive team and Board of Directors.
Neutral
GlobeNewsWire
1 month ago
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that three abstracts relating to the company's lead product candidate, ficerafusp alfa, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will be held from April 25-30, 2025 in Chicago, IL. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) and is being evaluated across multiple solid tumor types.
Neutral
GlobeNewsWire
2 months ago
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 3:10 p.m. ET.
Neutral
GlobeNewsWire
2 months ago
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).
Neutral
GlobeNewsWire
3 months ago
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
BOSTON, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the presentation of data from the Phase 1/1b dose expansion cohort of ficerafusp alfa in combination with pembrolizumab in patients with second line (2L) or later squamous cancer of the anal canal (SCAC). The results were presented in a poster session during the 2025 ASCO Gastrointestinal (GI) Cancers Symposium on Saturday, January 25, 2025. Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β), and is being evaluated in multiple solid tumor types.
Neutral
GlobeNewsWire
5 months ago
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters' option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended September 30, 2024 and provided a business update. “The third quarter of 2024 was momentous for Bicara, highlighted by the successful completion of our upsized initial public offering, providing us with a robust balance sheet to continue to advance the development of ficerafusp alfa, our bifunctional EGFR/TGF-β inhibitor designed to exert potent anti-tumor activity directly within the tumor microenvironment,” said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics.
Neutral
GlobeNewsWire
5 months ago
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced that Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics, will present at the Stifel 2024 Healthcare Conference in New York, NY on Tuesday, November 19, 2024 at 9:10 a.m. ET.
Charts implemented using Lightweight Charts™